Vice President, Pfizer
Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Medicinal Chemistry.Register Now
KEY OPINION LEADERS
The Medicinal Chemistry Roundtable Discussions Strategy Meeting is free to attend for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Vice President Medicinal Chemistry, C4 Therapeutics
Chris joined C4 Therapeutics in February 2016 and serves in the role of Vice President, Chemistry. Most recently, Chris was at the Broad Institute where he led a group of medicinal chemists in projects in the cancer, metabolism, and autophagy disease areas at the Center for the Development of Therapeutics. Prior to the Broad, Dr. Nasveschuk was an integral member of the team at Constellation Pharmaceuticals where he co-invented the EZH2 inhibitor CPI-1205 and helped to discover and develop the BET inhibitor CPI-0610. He holds a PhD in Organic Chemistry from Colorado State University and a BS in Chemistry from Middlebury College.
Vice President, Head of Drug Discovery, Quartet Medicine
Dr. Tebbe has more than 20 years of experience in drug discovery and development and is currently Vice President, Head of Drug Discovery at Quartet Medicine focusing on peripheral neuropathic pain and inflammation. He is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor. He was previously Vice President of Medicinal and Computational Chemistry at Forma therapeutics where he focused on small molecule cancer therapeutics. Prior to that, Dr. Tebbe held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry in Hamburg, Germany, and Research Triangle Park, North Carolina. He obtained his Ph.D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.
Executive Director, Head of Strategic Partnerships, TESARO
Keith Wilcoxen received his BS from Northwestern University and Ph.D. in Chemistry from Scripps Research Institute. Keith has spent nearly 20 years in therapeutic research and development at numerous companies, including Pfizer, Neurocrine Biosciences, Eisai and Tesaro Inc. and been involved in the development of several approved drugs, including most recently rolapitant and niraparib. Currently, Keith is Executive Director, Head of Strategic Partnerships at TESARO where he is responsible for generating new clinical candidates through partnered and collaborative research.
SponsorsSee All Of Our Sponsors
Medicinal Chemistry Strategy Meeting US East Coast 2016,
The Westin Boston Waterfront
425 Summer St, Boston, MA 02210